KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Receivables: 2010-2025

Historic Change in Receivables for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to $29.7 million.

  • Halozyme Therapeutics' Change in Receivables fell 58.30% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.3 million, marking a year-over-year decrease of 11.88%. This contributed to the annual value of $74.2 million for FY2024, which is 2123.57% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Change in Receivables of $29.7 million as of Q3 2025, which was up 153.42% from $11.7 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Change in Receivables high stood at $71.2 million for Q3 2024, and its period low was -$41.1 million during Q3 2021.
  • Its 3-year average for Change in Receivables is $10.5 million, with a median of $16.9 million in 2023.
  • The largest annual percentage gain for Halozyme Therapeutics' Change in Receivables in the last 5 years was 746.90% (2021), contrasted with its biggest fall of 263.41% (2021).
  • Halozyme Therapeutics' Change in Receivables (Quarterly) stood at -$21.1 million in 2021, then spiked by 136.71% to $7.8 million in 2022, then spiked by 117.73% to $16.9 million in 2023, then surged by 34.51% to $22.7 million in 2024, then crashed by 58.30% to $29.7 million in 2025.
  • Its last three reported values are $29.7 million in Q3 2025, $11.7 million for Q2 2025, and -$3.8 million during Q1 2025.